Phase II study of capecitabine (X) plus docetaxel (T) as neoadjuvant treatment in patients (pts) with locally advanced breast cancer (LABC) including biological correlates.

被引：0
|
作者：
Bellet, M.
Muñoz, M.
Bellosillo, B.
Corominas, J.
Pena, T.
Suárez, M.
Maristany, M.
Perich, J.
Tusquets, I.
Fabregat, X.
机构：
[1] Hosp del Mar, Barcelona, Spain
[2] Hosp Clin Barcelona, Barcelona, Spain
[3] Roche Farma, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：43S / 43S
页数：1
相关论文
共 50 条
  • [21] Phase II trial of docetaxel plus doxorubicin and cyclophosphamide in locally advanced breast cancer (LABC).
    Puertolas, T
    Grandez, R
    de Lobera, AR
    Lao, J
    Herrero, A
    Trufero, JM
    Pazo, R
    Orduña, VA
    Cortes, AA
    Torres, AA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 89S - 89S
  • [22] Epirubicin and docetaxel as neoadjuvant treatment of locally advanced breast cancer: a phase II study
    Lombardi, D.
    Scalone, S.
    Crivellari, D.
    La Mura, N.
    Miolo, G.
    Murrone, A.
    Perin, T.
    Coran, F.
    Candiani, E.
    Massarut, S.
    Veronesi, A.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S229 - S229
  • [23] Epirubicin and docetaxel as neoadjuvant treatment of locally advanced breast cancer: a phase II study
    Lombardi, Davide
    Scalone, Simona
    Crivellari, Diana
    Magri, Maria Donatella
    La Mura, Nicoletta
    Miolo, GianMaria
    Murrone, Antonio
    Perin, Tiziana
    Coran, Francesco
    Candiani, Ezio
    Massarut, Samuele
    Veronesi, Andrea
    TUMORI JOURNAL, 2010, 96 (02): : 229 - 233
  • [24] Capecitabine chemoradiation (X-RT) as neoadjuvant therapy for patients (pts) with locally advanced breast cancer (LABC) refractory to anthracyclines.
    Gaui, MF
    Amorim, G
    Arcuri, R
    Pereira, G
    Moreira, D
    Djahjah, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 52S - 52S
  • [25] Neoadjuvant sequential treatment with epirubicin plus docetaxel followed by capecitabine plus docetaxel in locally advanced breast cancer:: XELOGET:: a pilot study.
    Bourgeois, H.
    Soulie, P.
    Delva, R.
    Abadie-Lacourtoisei, S.
    Van Praagh, I
    Mouret-Reynier, M-A
    Lortholary, A.
    Chieze, S.
    Raban, N.
    Mac Grogan, G.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S155 - S155
  • [26] Phase II study of capecitabine (C) in combination with docetaxel (D) as neoadjuvant treatment in patients with locally advanced breast cancer (IIIA and IIIB stage).
    Bellet, M
    Munoz, M
    Pelegri, A
    Corominas, J
    Bellosillo, B
    Tusquets, I
    Fabregat, X
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 64S - 64S
  • [27] Phase II study of dose-dense docetaxel (T) and epirubicin (E) as neoadjuvant treatment for locally advanced breast cancer (LABC).: An ONCOPAZ Cooperative Group
    Lorenzo, A
    Madroñal, C
    Sanz, JJ
    Centelles, M
    López, MR
    Casas, A
    Péez, VG
    de la Puente, CG
    López, MJG
    Borrega, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 72S - 72S
  • [28] Neoadjuvant capecitabine chemoradiation (X-RT) for patients (pts) with locally advanced breast cancer (LABC) failing anthracycline-based neoadjuvant therapy: findings from a prospective phase II trial
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 151 - 151
  • [29] Progranulin (PC-derived growth factor) levels in serum do not predict response to neoadjuvant capecitabine (X), docetaxel (T) and trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC)
    Wildiers, H.
    Buysschaert, I.
    Van Hootegem, A.
    Smeets, A.
    Vanden Bempt, I.
    Neven, P.
    Moerman, R.
    Schoffski, P.
    Paridaens, R.
    Lambrechts, D.
    BREAST, 2009, 18 : S64 - S65
  • [30] A phase II trial of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer.
    Lu, YS
    Kuo, SH
    Su, WP
    Yang, CH
    Hsu, C
    Yang, TL
    Huang, CS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 93S - 93S
12345